Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Retatrutide is designed to activate three key metabolic receptors: GLP-1, GIP, and glucagon
RetatrutideMounjaro (Tirzepatide)Wegovy (Semaglutide) Mechanism Triple (GLP-1 + GIP + Glucagon)Dual (GLP-1 + GIP)Single (GLP-1) Best weight loss in trials 30.3%22.5%20.7% Trial duration 104 weeks72 weeks72 weeks UK approval Not yetYes (Mounjaro)Yes (Wegovy) Injection frequency Once weeklyOnce weeklyOnce weekly One important caveat: the 30.3% figure comes from a 104-week trial, while the Mounjaro and Wegovy results are from 72-week trials
Tirzepatide has been associated with an increased risk of gallstones and cholecystitis
Because they serve different purposes, they can complement each other: Sermorelin supports hormone balance and recovery BPC-157 focuses on healing damaged tissues For example, someone whos training regularly but dealing with a lingering injury may benefit from both approaches, one supporting recovery overall, the other targeting the injury itself
Heartburn is one of the most commonly reported side effects among patients taking semaglutide (Ozempic, Wegovy, Rybelsus), a GLP-1 receptor agonist used for type 2 diabetes and weight management
US$ 27.61
US$ 29.24
US$ 25.28
US$ 26.27
US$ 21.98
